RADAR
RADAR
RADAR is a free, online publication that provides independent, timely and evidence-based communications to health professionals about new and revised listings on the Pharmaceutical Benefits Scheme (PBS).
About RADAR
RADAR provides independent, timely and evidence-based information to health professionals about new and revised listings on the Pharmaceutical Benefits Scheme (PBS). This information assist prescribers to make informed prescribing decisions and provide optimal care.
Stay up to date
For future updates on RADAR Issues, follow us on @ACSQHC or subscribe to our eNewsletters.
Read the latest issue
Issue #1 - July 2024
The July 2024 issue of RADAR is out now. This issue provides a wrap-up of medicines recently revised on the PBS including:
- Nirmatrelvir and ritonavir (Paxlovid®) and molnupiravir (Lagevrio®) for COVID-19 (amended PBS listing)
- Type 2 diabetes mellitus (T2DM) medicines (amended PBS restrictions).
This document was accurate at the time of publication. However, changes to the PBS have been made since publication, which are not reflected in the July issue. For the most current information, please visit the PBS website.
- PBS eligibility criteria changes for COVID-19 medicines molnupiravir (Lagevrio®) and nirmatrelvir and ritonavir (Paxlovid®)
- PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines